Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
101. |
ECCT/21/11/07 | lidERA A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTORï€POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER |
Principal Investigator(s) 1. Fredrick Asirwa Chite Site(s) in Kenya 1. International Cancer Institute (ICI) (Uasin Gishu county) 2. Aga Khan University Hospital (Nairobi City county) |
27-03-2022 |
View |
102. |
ECCT/21/11/08 | GBT_131 Inclacumab-Ps 3 Trial. A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vaso-occlusive Crises |
Principal Investigator(s) 1. Videlis N Nduba 2. Prof. Jessie N Githanga 3. Fredrick Sirwa Chite 4. Bernhards Ragama Ogutu Site(s) in Kenya 1. KEMRI/CRDR (Nairobi City county) 2. KEMRI Siaya Clinical Research Annex (Siaya county) 3. Gertrude’s Children’s Hospital. (Nairobi City county) 4. Strathmore University Medical Centre (Nairobi City county) 5. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county) |
02-02-2022 |
View |
103. |
ECCT/21/12/05 | 131 Inclacumab Ph 3 Trial. A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vasoocclusive Crises |
Principal Investigator(s) 1. Bernhards Ragama Ogutu 2. Fredrick Asirwa Chite 3. Videlis N Nduba 4. Prof. Jessie N Githanga Site(s) in Kenya 1. Strathmore University Medical Centre (Nairobi City county) 2. KEMRI/CRDR (Nairobi City county) 3. KEMRI Siaya Clinical Research Annex (Siaya county) 4. Gertrude’s Children’s Hospital. (Nairobi City county) 5. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county) |
22-03-2022 |
View |
104. |
ECCT/21/12/07 | GBT 132- Inclacumab Phase 3 A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso-occlusive Crises. |
Principal Investigator(s) 1. Bernhards Ragama Ogutu 2. Videlis N Nduba 3. Fredrick Asirwa Chite Site(s) in Kenya 1. Strathmore University Medical Centre (Nairobi City county) 2. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county) 3. KEMRI/CRDR (Nairobi City county) 4. KEMRI Siaya Clinical Research Annex (Siaya county) |
21-03-2022 |
View |
105. |
ECCT/22/01/01 | ASTEFANIA A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ATEZOLIZUMAB OR PLACEBO AND TRASTUZUMAB EMTANSINE FOR HER2-POSITIVE BREAST CANCER AT HIGH RISK OF RECURRENCE FOLLOWING PREOPERATIVE THERAPY |
Principal Investigator(s) 1. Mansoor Saleh 2. Fredrick Chite Asirwa Site(s) in Kenya 1. Aga Khan University, Nairobi (Nairobi City county) 2. International Cancer Institute (Uasin Gishu county) |
21-07-2022 |
View |
106. |
ECCT/22/01/03 | lidERA A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared with Physician’s Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer |
Principal Investigator(s) 1. Mansoor Saleh Site(s) in Kenya 1. International Cancer Institute (ICI) (Uasin Gishu county) 2. Aga Khan University Hospital (Nairobi City county) |
08-05-2022 |
View |
107. |
ECCT/22/01/04 | SKYSCRAPER 07 A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNRESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA WHOSE CANCERS HAVE NOT PROGRESSED FOLLOWING DEFINITIVE CONCURRENT CHEMORADIOTHERAPY |
Principal Investigator(s) 1. Fredrick Chite Asirwa 2. Mansoor Saleh Site(s) in Kenya 1. Aga Khan University, Nairobi (Nairobi City county) 2. International Cancer Institute (Uasin Gishu county) |
22-05-2022 |
View |
108. |
ECCT/22/01/05 | STEP-Mag Trial Simplified Treatment for Eclampsia Prevention using Magnesium sulfate: A phase III, randomized, open label, active controlled, multicountry, multicentre, non-inferiority trial of simplified magnesium sulfate regimen for eclampsia prophylaxis (The STEP-Mag Trial) |
Principal Investigator(s) 1. Zahida Qureshi Site(s) in Kenya 1. Wamalwa Kijana TRH (Trans Nzoia county) 2. Mama Lucy Kibaki Hospital (Nairobi City county) 3. Mbagathi County referral Hospital (Nairobi City county) |
15-05-2022 |
View |
109. |
ECCT/22/01/06 | AIKILI Technology Feasibility and accuracy of nanosensor-based breast cancer diagnosis at the point-of-care-AIKILI technology |
Principal Investigator(s) 1. Laura Kelley Kelley Site(s) in Kenya Aga Khan University Hospital, Nairobi. |
21-03-2022 |
View |
110. |
ECCT/22/02/01 | An Open label Inclacumab study An Open-Label Extension Study to Evaluate the Long-Term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial |
Principal Investigator(s) 1. Bernhards Ragama Ogutu 2. Fredrick Asirwa Chite 3. Videlis N nduba 4. Prof Jessie N Githanga Site(s) in Kenya 1. Strathmore University Medical Centre (Nairobi City county) 2. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county) 3. KEMRI/CRDR (Nairobi City county) 4. KEMRI Siaya Clinical Research Annex (Siaya county) 5. Gertrude’s Children’s Hospital. (Nairobi City county) 6. Strathmore University Medical Centre (Nairobi City county) |
16-05-2022 |
View |